Lytix Biopharma presented on September 6th new clinical Phase II data on the Company’s topical antimicrobial drug, LTX-109, at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C. Data presented demonstrated the clinical efficacy of LTX-109 in patients with impetigo.
“LTX-109 – a novel antimicrobial peptide in the treatment of impetigo” [F-252] Sat, Sep. 6, 2014, 12:00 PM - 2:00 PM, Poster Session Title: Antimicrobial Peptides, Exhibit Hall B/Walter E. Washington Convention Center
Lytix Biopharma was presented by Wenche Marie Olsen, COO, and Hedda Wold, Project Manager, Infectious Diseases.
Hedda Wold, Wenche Marie Olsen and the doctors in charge of the clinical study - Daisy Blanco,
Josefina Fernandez og Elfida Sanches.
A poster demonstrating the post antibiotic effect of LTX-109 was also presented at ICAAC. This work has been led by professor Louis Saravolatz and his team at St John Hospital and Medical Center, Detroit, USA.
Louis Saravolatz, Joan Pawlak and Wenche Marie Olsen.